R&D channel feed – Endpoints News

R&D channel feed

Still haunted by its founder’s scandalous past, Kadmon scores a $75M IPO

9 years ago

J&J joins the combo lineup at Bristol-Myers, where a new wagon master runs oncology R&D

9 years ago

Building a bulletproof CAR? Scientists engineer a built-in PD-1 shield

9 years ago

Tokai’s prostate cancer drug implodes in PhIII debacle

9 years ago

What's Gilead's next deal going to look like? CEO Milligan cites blockbuster filgotinib pact

9 years ago

Celgene’s Revlimid flops in Phase III lymphoma study, shares slide

9 years ago

Kite grabs a stem cell biology ‘breakthrough’ in race for off-the-shelf T cell therapies

9 years ago

Protocols: Tricida bags $55M round for CKD drug; $MRK gets a 'breakthrough’;

9 years ago

PTC faces a delay in Europe for controversial Duchenne drug

9 years ago

Eyeing an IPO, Alzheon looks to raise $100M for a “derisked” Alzheimer’s PhIII

9 years ago

Tobira crushed after NASH drug flunks a PhIIb, but slice of data drives PhIII plans

9 years ago

FDA lifts a hold on a Novartis hearing loss drug, and tiny GenVec gets a lift

9 years ago

AbbVie hustles its unicorn drug Rova-T into the clinic in combo with Bristol's Opdivo

9 years ago

Shire bags a quick thumbs up for its newly won cancer drug pipeline

9 years ago

Are 'great' tweeters born? Or can they be made? A conversation with Adam Feuerstein.

9 years ago

Top stories of the week: Thumbs up/Thumbs down

9 years ago

Pfizer/Spark team gets a ‘breakthrough’ in gene therapy alliance

9 years ago

Funded for PhII, biotech entrepreneurs achieve a 15-year-old R&D dream

9 years ago

Exhibit A in Valeant’s blockbuster R&D boast runs into trouble at the FDA

9 years ago

What’s the hottest biotech R&D field in venture investing?

9 years ago

Rhythm eyes a pivotal test after rolling through PhII with upbeat results for rare obesity cases

9 years ago

With biosimilars gaining momentum, Amgen and Allergan cite success of Herceptin's copycat

9 years ago

The Scangos legacy: A blockbuster MS record with lingering doubts about the pipeline

9 years ago

Sidelined at the FDA, AstraZeneca watches as new team seizes rival drug in $1.5B Relypsa buyout

9 years ago

First page Previous page 324 325 326327328 329 330 Next page Last page